PROGRAMME ON DEMAND

2nd How to Diagnose and Treat
ACUTE LEUKAEMIA
Virtual Conference - #ESHAL2020
June 30 – July 2, 2020
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

The pre-recorded Case based lectures will be available "on demand" as of Saturday, June 20, 2020. The other sessions will be recorded "live", as they take place, and will be available "on demand" as soon as they are over.
By the end of the meeting and until July 12, 2020, the full scientific programme will be available on the e-Platform "on demand" to enable registered participants to view all presentations and discussions at times convenient to them, regardless of their time zone.

15'	**Welcome**	
15'	**Keynote lecture - COVID 19 and AML**	Jorge Sierra (Barcelona)
10'	*Discussion*	
95'	**Rare subsets of acute leukaemia** **Chair:** Gail Roboz (New York)	
20'	Case-based lecture : Mixed phenotype acute leukaemias (B/M)	Charles Mullighan (Memphis)
20'	Case-based lecture : Interface acute leukaemias (T/M)	Jonathan Bond (Dublin)
20'	Case-based lecture : Germline predisposition to AML	Lucy Godley (Chicago)
Brief oral communication		
5'	*Dasatinib inhibits FLT3/itd and PTPN11 mutated acute myeloid leukemia cells overexpressing SRC Tyrosine kinases*	Nathali Kaushansky (Rehovot)
30'	*Panel discussion*	
95'	**Tracking leukaemic stem cells (LSCs)** **Chair:** Sylvie Freeman (Birmingham)	
20'	Case-based lecture : LSC signature	Tracy Murphy (Toronto)

20'	Case-based lecture : Flow identification and monitoring of leukaemia stem cells	Jacqueline Cloos (Amsterdam)
20'	Case-based lecture : MRD monitoring in Ph-positive ALL	Emmanuelle Clappier (Paris)
Brief oral communication		
5'	*Circulating microRNAs behaving as minimal residual disease biomarkers in childhood ALL*	Dániel János Erdélyi (Budapest)
30'	*Panel discussion*	

95' **Routine diagnosis gene expression and mutational profiling**
Chair: Oliver Ottmann (Cardiff)

20'	Case-based Lecture : Ph-like ALL diagnosis	Sabina Chiaretti (Rome)
20'	Case-based lecture : Minimal / optimal gene panel in ALL ?	Josep-Maria Ribera (Barcelona)
20'	Case-based lecture : Minimal / optimal gene panel in AML ?	Lars Bullinger (Berlin)
Brief oral communication		
5'	*Integrated whole genome-transcriptome sequencing compared to conventional diagnostic testing in adult B-ALL*	Georgina Ryland (Melbourne)
30'	*Panel discussion*	

50' **DEBATE – All patients with intermediate-risk AML must be transplanted**
Chair: Andrew Wei (Melbourne)

15'	Yes	Charles Craddock (Birmingham)
15'	No	Gail Roboz (New York)
20'	*Discussion*	

30' **INTERACTIVE CASES – Mutation-based therapy off-label**
Chair: Jorge Sierra (Barcelona)

7'	Targeted therapy for Ph-like ALL	Sarah Tasian (Philadelphia)
3'	*Discussion*	
7'	Mutation-based therapy off-label - GO for AML salvage therapy	Nicolas Boissel (Paris)
3'	*Discussion*	
7'	FLT3 inhibitors post-transplantation	Andreas Burchert (Marburg)
3'	*Discussion*	

60'	**ROUNDTABLE – Should we really use new targeted inhibitors as single agents ?** **Chair:** Christoph Röllig (Dresden)	
20'	Next-generation FLT3 inhibitors	Alexander Perl (Philadelphia)
20'	The role of IDH1/2 inhibitors as monotherapy	Courtney DiNardo (Houston)
20'	*Discussion*	
	Mentored Poster Walk	Nicolas Boissel (Paris), Oliver Ottmann (Cardiff)
60'	**3 Simultaneous Meet the Expert sessions**	
	1. CNS prophylaxis and treatment in ALL	Wendy Stock (Chicago)
	2. MRD as a treatment-stratifying tool in AML	Sylvie Freeman (Birmingham)
	3. Acute leukaemia and pregnancy	Nicolas Boissel (Paris)
95'	**Addition of a 3rd agent to frontline 7+3** **Chair :** Andrew Wei (Melbourne)	
20'	Case-based lecture : Midostaurin	Jorge Sierra (Barcelona)
20'	Case-based lecture : Addition of gemtuzumab ozogamicin to front line 3+7 chemotherapy	Juliette Lambert (Versailles)
20'	Case-based lecture : Nucleoside analogues in high-risk AML	Nigel Russell (Nottingham)
Brief oral communication		
5'	*Updated results from a phase 1 study of Gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML*	Alexander Perl (Philadelphia)
30'	*Panel discussion*	
65'	**ROUNDTABLE – Curative options for older AML** **Chair:** Alexander Perl (Philadelphia)	
15'	Current intensive therapy of older AML patients in 2020	Thorsten Braun (Bobigny)
15'	Liposomal daunorubicin/cytarabine	Jorge E. Cortes (Augusta)
15'	Defining the role of Venetoclax in older patients with AML	Andrew Wei (Melbourne)
20'	*Discussion*	
20'	**INTERACTIVE CASES 2** **Chair:** Arnold Ganser (Hannover)	
7'	Management of high WBC APL	Pau Montesinos (Valencia)
3'	*Discussion*	

7'	APL relapse after previous arsenic therapy	Pierre Fenaux (Paris)
3'	*Discussion*	

50' **DEBATE – Best treatment for NPM1-mutated AML in the next future ?**
Chair: Hervé Dombret (Paris)

15'	Treatment of NPM1-mutated AML: intensive standard treatment!	Christoph Röllig (Dresden)
15'	Targeted agents	Ali Bazarbachi (Beyrouth)
20'	*Discussion*	

95' **Allogeneic haematopoietic stem cell transplantation (HSCT)**
Chair: Charles Craddock (Birmingham)

20'	Case-based lecture : New GvHD prophylactic/curative treatment	Jean-Hugues Dalle (Paris)
20'	Case-based lecture : Haplo-identical HSCT with acute leukaemia	Jorge Sierra (Barcelona)
20'	Case-based lecture : Prevention and treatment of VOD – 100 years after the "Senecio Disease"	Sergio Giralt (New York)

Brief oral communication

5'	*Detectable minimal measurable disease by flow cytometry before allogeneic transplantation is a factor of poor outcomes in acute myeloid leukemia*	*Claudia Núnez-Torrón Stock (Madrid)*
30'	*Panel discussion*	

60' **3 Simultaneous Breakfast Meet the Expert Sessions**

1.	Therapy-related leukaemias	Arnold Ganser (Hannover)
2.	How I treat Ph+ ALL	Oliver Ottmann (Cardiff)
3.	How I treat older ALL	Hervé Dombret (Paris)

95' **Immunotherapy for acute leukaemia**
Chair: Wendy Stock (Chicago)

20'	Case-based lecture : Use of blinatumomab in ALL	Anita Rijneveld (Rotterdam)
20'	Case-based lecture : CAR T-cells for precursor B-cell ALL	Françoise Méchinaud (Paris)

20'	Case-based lecture : Immune check-point inhibitors in acute leukaemia	Navel Daver (Houston)

Brief oral communication

5'	*Phase 1b multicenter, open-label study of the anti–TIM-3 antibody MBG453 in combination with decitabine in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)*	Andrew Wei (Melbourne)
30'	*Panel discussion*	
50'	**DEBATE – T-ALL: where are we going now?** **Chair:** Nicolas Boissel (Paris)	
15'	Standard and new options for T-ALL	David Teachey (Philadelphia)
15'	Targeting T cell malignancies with CRISPR/Cas9 Gene Edited Universal CART	John DiPersio (Saint-Louis)
20'	*Discussion*	

60' **SATELLITE SYMPOSIUM:**
T-cell engaging immuno-oncology therapy in ALL: from clinical trials to real-world evidence
Speakers: Nicolas Boissel (Paris), Christina Peters (Vienna)

This symposium is organised and funded by Amgen

60' **SATELLITE SYMPOSIUM:**
AML treatment: Where are we heading?
Chair : Andrew Wei (Melbourne)
Speakers: Konstanze Döhner (Ulm), Gail Roboz (New York)

This symposium is organized and funded by Celgene. A Bristol-Myers Squibb company

60' **SATELLITE SYMPOSIUM:**
AML: Bringing precision medicine and MRD into clinical strategies
Chair : Jorge Sierra (Barcelona)
Speakers: Lionel Adès (Paris), Lars Bullinger (Berlin), Jorge Sierra (Barcelona)

This symposium is organised and funded by Novartis

60' **SATELLITE SYMPOSIUM:**
Clinical perspectives in AML: Diagnosis, monitoring and treatment
Chair : Jorge Sierra (Barcelona)
Speakers: Jacqueline Cloos (Amsterdam), Pau Montesinos (Valencia), Jorge Sierra (Barcelona), Andrew Wei (Melbourne)

This symposium is organised and funded by Astellas